Intensity‐modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost‐effectiveness analysis
| العنوان: | Intensity‐modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost‐effectiveness analysis |
|---|---|
| المؤلفون: | Chao-Nan Qian, Yi-Xiang Huang, Guo Li, Jin Gao, Jérôme Doyen, Karen Benezery, Bo Qiu, Pierre-Yves Bondiau, Yun-Fei Xia, Deniz Okat |
| المصدر: | Head & Neck. 44:431-442 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Radical treatment, medicine.medical_specialty, Nasopharyngeal Carcinoma, business.industry, Cost-Benefit Analysis, Photon radiation therapy, Nasopharyngeal Neoplasms, Cost-effectiveness analysis, medicine.disease, Proton radiation therapy, Dysphagia, Intensity (physics), Otorhinolaryngology, Nasopharyngeal carcinoma, Proton Therapy, otorhinolaryngologic diseases, medicine, Humans, Radiotherapy, Intensity-Modulated, Radiology, Protons, medicine.symptom, Complication, business |
| الوصف: | Background Compared to conventional intensity-modulated photon radiation therapy (IMRT), intensity-modulated proton radiation therapy (IMPT) has potential to reduce irradiation-induced late toxicities while maintaining excellent tumor control in patients with nasopharyngeal carcinoma (NPC). However, the relevant cost-effectiveness remains controversial. Methods A Markov decision tree analysis was performed under the assumption that IMPT offered normal tissue complication probability reduction (NTCP reduction) in long-term dysphagia, xerostomia, and hearing loss, compared to IMRT. Base-case evaluation was performed on T2N2M0 NPC of median age (43 years old). A Chinese societal willingness-to-pay threshold (33558 US dollars [$])/quality-adjusted life-year [QALY]) was adopted. Results For patients at median age and having NTCP reduction of 10%, 20%, 30%, 40%, 50%, and 60%, their incremental cost-effectiveness ratios were $102684.0/QALY, $43161.2/QALY, $24134.7/QALY, $13991.6/QALY, $8259.8/QALY, and $4436.1/QALY, respectively; IMPT should provide an NTCP reduction of ≥24% to be considered cost-effective. Conclusions IMPT has potential to be cost-effective for average Chinese NPC patients and should be validated clinically. |
| تدمد: | 1097-0347 1043-3074 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d7edfc3a4ac60b0ea29182198a2fb0 https://doi.org/10.1002/hed.26941 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....d2d7edfc3a4ac60b0ea29182198a2fb0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10970347 10433074 |
|---|